clinical trial · NCT07486869
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
University of Miami·phase2·recruiting·n = 5
DermatomyositisDermatomyositis Sine MyositisDermatomyositis With MyopathyDermatomyositis With Respiratory InvolvementDermatomyositis With Organ InvolvementInterstitial Lung DiseaseInterstitial Lung Disease Due to Connective Tissue Disease (Disorder)Emapalumab
brief summary
This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.
started
Jul 23, 2026
primary completion
Jul 1, 2027
completion
Jul 1, 2027
last updated
Aug 25, 2026
official title
Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol